Philips has signed a deal with diagnostics developer Biodesix to add data from that company's proteomic lung nodule risk assessment test to Philips' Lung Cancer Orchestrator patient management software.
Proteomics data from Biodesix's Nodify Lung test will be integrated into Lung Cancer Orchestrator and will appear alongside medical imaging and patient history data to help guide treatment decisions. Philips developed Lung Cancer Orchestrator to help healthcare systems roll out lung cancer screening and nodule management programs on a broad scale.
Nodify Lung helps clinicians reclassify the risk of malignancy to better target resources to patients who need them. If a nodule is malignant, Biodesix notes that a four-week delay in surgical care for cancer patients could increase their risk of mortality by 6-8%.
